Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Delforge, Michel  [Clear All Filters]
2023
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.
Gagelmann N, Eikema D-J, Koster L, Netelenbos T, McDonald A, Stoppa A-M, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, et al. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. Eur J Haematol. 2023.
Avivi I, Vesole DH, Dávila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, Baumert B, Osękowska B, Kopińska A, Gentile M, et al. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients. Cancers (Basel). 2023;15(17).
Manier S, Dimopoulos M, Hulin C, Leleu X, Delforge M, Weisel K, Mouro J, Costa B, Sturniolo M, Facon T. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis. Clin Lymphoma Myeloma Leuk. 2023.
Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
2018
Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Dávila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2018:1-6.
2014
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med. 2014;371(10):906-917.